The pretreatment principle in renal transplantation as illustrated by thoracic duct drainage by Starzl, TE et al.
From: eHRONI" pr~g""yl ij·· 'SEA"""'-
'-- • ~;;_ "~DDDDl .. .,. ", ~ ~~ 
",1 EdAit8NdObSY N,oncy Saucot Cummings, M.D. 
t I' au 0 K!unr, M.D. 
" .J. (Plenum Publishing Corporation, 1985) 
51 
The Pretreatment Principle in Renal 
Transplantation as Illustrated by 
Thoracic Duct Drainage 
Thomas E. Starzl, Richard Weil, III, and 
Lawrence J. Koep 
In spite of all that has been achieved, renal transplantation still provides a 
flawed and unpredictable service. In the average American center in the 
decade of the seventies, less than half the recipients of first cadaver kidneys 
had graft function by the end of the first postoperative year. One reason 
may be neglect of what has been called the "forgotten pretreatment principle." 
It is that subject which is addressed here, with particular emphasis on thoracic 
duct drainage (TDD). 
1. Early Clues 
In 25 of our first kidney reCIpIents, Wilson and Kirkpatrick(31) used 
preoperative skin testing and typhoid vaccination to assess cellular and 
humoral immune reactivity. Immunosuppressive therapy for those patients 
was with azathioprine to which prednisone was added only if rejection 
developed,09,20) After transplantation, the patients previously classified as 
non responders had a mean rejection time of 14.8 days, compared to 4.3 
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days in the responders. These findings were not influenced by donor 
relationship. Wilson and Kirkpatrick concluded that 
These observations support the concept that impaired immunologic responsiveness 
in uremia is an important factor in successful human kidney transplantation. 
Furthermore, the difference in rejection times between the responsive and unres-
ponsive groups suggests that the reactive group might benefit from additional 
immunosuppressive therapy prior to [transplantation] .... 
Almost a decade later, the prognostic implication of the reactor-versus-
non reactor state of kidney recipients was reemphasized by the antibody 
studies of Opelz, Mickey, and Terasaki.o6) More recently, Jones et al.,(8) 
Thomas et al.,<27) and Opelz and Terasaki(l'i) came to the same conclusion 
from the results of in vitro phytohemagglutin, concanavalin A, and mixed-
lymphocyte culture (MLC) tests all of which are expressions of T-lymphocyte 
reactivity. The MLC studies(l5) were particularly illuminating. The MLC 
index using third-party lymphocytes was almost as predictive of the outcome 
after cadaveric kidney transplantation as when the stimulator cells were 
provided by the actual donor. 
Although well known, the foregoing information has had surprisingly 
little influence on treatment practices. In the early days of our program 
almost all human kidney recipients were given azathioprine for 8-10 days 
before transplantation. The practice was based on analogous canine experi-
ments in which average homograft survival was doubled thereby over that 
obtained when the drug was started on the day of operation.o9) Gradual 
abandonment of the policy of preoperative treatment of our patients with 
azathioprine, and often steroids may have been a systematic error inasmuch 
as other immunosuppressive adjuncts to condition the recipients were not 
being substituted. As cadaveric transplantation became more common, prac-
tical reasons made pretreatment difficult. The waiting period for a cadaver 
kidney was unpredictable, during which time extra infectious risks were 
introduced by giving azathioprine with or without prednisone. Furthermore, 
there were no accepted guidelines about the appropriate duration of such 
pretreatment. Worldwide, transplantation centers drifted into the practice 
of starting therapy on the day of grafting. 
2. TDD and the Pretreatment Principle 
The immunosuppressive procedure of TDD has provided an unusually 
analyzable example of the pretreatment principle and of the loss of much 
of the value of this procedure if its timing is wrong. TDD was given a trial 
in several centers 5-15 years ago(I-6.11-13.17,18.28,29) but was never accepted 
as a major therapeutic tool. This was because the scientific framework for 
its use in humans had not been worked out. 
3. Contemporaneous TDD 
Eighteen months ago we began a systematic trial with TDD in renal 
transplantation, starting the lymphoid depletion on the day of grafting along 
'0 , 
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Table 1. Rejection in First 2 Months of Cadaver Kidneys: Influence of TDDa 
Incidence rejection 
Irreversible rejection 
Deaths 
Contemporaneous 
TDD (I7)b 
41% 
24% 
o 
Percent rejection 
3 Weeks 
pretreatment 
with TDD (13) 
38% 
8% 
1 
2!4 Weeks 
pretreatment 
with TDD (14) 
7% 
0% 
2 
a In 50 immediately precedent cadaveric recipients treated with azathioprine, prednisone, and sometimes 
ALG, the incidence of early rejection was 48%.(22) 
b Data from ref. 22. 
with azathioprine, prednisone, and sometimes antilymphocyte globulin 
(ALG).(22.23) The protocol was similar to that usually used by Franksson et 
al.(5) The results were somewhat better than in historical controls without 
TDD, but vigorous rejection was often encountered during the first month 
(Table 1). The most striking clinical observation was that if the TDD was 
continued, a second graft could often be performed after failure of the 
first. (23) It was obvious that TDD was being inappropriately used for the 
primary transplant. Data in these patients plus precise immunologic studies 
by Machleder and Paulus(lO) in nontransplantation patients established that 
a pronounced immunodepressive influence of TDD was not established until 
about 3 weeks and that this effect deepened for another week or so. Kidneys 
in our early TDD series were being rejected during this uncovered 3 or 4 
weeks and, in addition, "antibody storms" in the postoperative period were 
often seen(23) with a heavy representation of the so-called warm anti-T and 
anti-B cytotoxic antibodies of the IgG class.(26) 
4. Pretreatment with TDD 
To correct the flaw in therapeutic strategy,(23) a new series was begun 
using TDD in advance of cadaveric renal transplantation,(24) adding azathio-
prine and prednisone on the day of operation. This time, the presence of 
preexisting recipient antibodies was taken into consideration. These antibod-
ies recently were characterized on the basis of their reactivity against 
homologous T and B lymphocytes at warm (lgG class) and cold (IgM) 
temperatures. (26) It has been accepted that warm anti-T antibodies cause 
hyperacute rejection,(26) but the significance of the other antibody varieties 
has remained controversial. Whatever their meaning, the cytotoxic antibodies 
could be construed as an index of the patients' immune reactivity, both by 
their presence before and by their development after transplantation. In the 
new treatment scheme, patients with no (or only cold) antibodies were 
scheduled for 3 weeks' preparation with TDD. Those possessing warm 
antibodies were scheduled for 35 days. If anti-T antibodies persisted and 
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Figure I. Example of short pretreatment with TDD. Although the patient had a perfect result, 
it is now known that the conditioning period was too brief. The drop in lymphocytes removed 
during the pretransplantation period was invariably observed. This finding was in contrast to 
our experience with TDD started on the day of transplantation in which the number of 
lymphocytes removed remained high. (The postoperative retention of TDD for about 3 weeks 
is still our policy.) The patient has had no evidence of late rejection. 
reacted against the potential donors, it was shown eariier(23) that a low titer 
was necessary before proceeding in the face of a positive cross match. After 
35 days, acceptance of cadaver donors whose positive cross matches were 
due to other kinds of antibodies was recommended. 
The recipients in this new series represented a modern-day cross section 
of risk factors. Many of the patients were old with known coronary artery 
disease, three were diabetics, and three were undergoing retransplantation. 
Because the donor selection was random except for red-ceIl-group compat-
ibility, the HLA and DR matches were all pOOr.(24) The results from the 
studies permitted precise conclusions about TDD pretreatment. 
4.1. Pretreatment of 3 Weeks 
Thirteen consecutive cadaver recipients of whom only one had preex-
isting warm anti-B antibodies had preoperative TDD for 17-28 days. The 
therapeutic approach is illustrated in Fig. 1. During the pretreatment 
period, the numbers of collected lymphocytes always fell markedly. After 
transplantation, the TDD was maintained for at least 3 more weeks. 
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Table 2. Broadly Reacting" Warm Anti-B Lymphocyte Antibodies 
2 Weeks after Transplantation 
TDD pretreatment for 3 weeks 7/13 
TDD pretreatment ;;::4 weeks 1114 
" Broadly reacting means reactivity against half or more of a 30·donor lympho· 
cyte panel. 
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During follow-ups of 2-6 months, five of these patients (38%) had 
rejection, which in four instances was reversible (Table 1). The fifth patient 
was treated with prompt retransplantation. These patients retained a potent 
capacity for cytotoxic antibody production. Two weeks after transplantation 
11 of the 13 had developed warm anti-B antibodies against a panel of 30 
lymphocyte donors, and in seven cases the antibodies reacted against more 
than half the panel (Table 2). All five of the rejections were in these latter 
seven antibody-producing recipients. One patient died 1 month after trans-
plantation from acute pancreatitis. 
4.2. Pretreatment for 4 Weeks or Longer 
Fourteen consecutive cadaveric recipients, of whom four had preexisting 
warm antibodies, had the longer pretreatment of 26-58 days. After 2-6 
months only one (7%) patient had a rejection (Table 1) and that one was so 
minor as to be equivocal. At the same time, the capacity to generate all 
categories of cytotoxic antibodies was remarkably reduced. Even though 4 of 
the 14 recipients already had warm antibodies predating TDD, these tended 
to diminish during pretreatment, and only 1 of the 14 possessed broad 
reacting warm antibodies 2 weeks posttransplantation (Table 2). 
Two patients died, one from a virus infection after 7 weeks, and the 
other at 2 months from a massive lidocaine overdosage given inadvertently 
by her family physician. 
5. Long-Term Implications 
In these patients, it remains to be seen if a delayed immunologic rebound 
will cause major kidney losses after discontinuance ofTDD. However, Walker, 
(30) johnson,(7) and Niblack(l4) and their associates have not seen a catch-up 
deterioration of grafts in patients followed 2-5 years after preoperative and 
postoperative TDD. Late stability after earlier TDD was also reported recently 
by Kaplan.(9) It seems likely that the poorly understood change in host-graft 
relationship that has made clinical transplantation practical will be expedited 
rather than hindered by properly timed TDD. If so, improvements in early 
graft survival should be translated into better long-term results. 
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6. Broader Implications 
If the pretreatment principle delineated by the foregoing experience is 
valid, it will influence other developments and practices in transplantation. 
6.1. Other Therapeutic Regimens 
It would be surprising if host conditioning, equivalent to that of chronic 
TDD, could not be achieved with other means over a period of several weeks. 
An obvious possibility is mechanical removal of lymphocytes from the 
peripheral blood (lymphapheresis), a procedure for which commercial in-
strumentation is already available. We have treated two liver recipients and 
one kidney recipient in this way. The procedures of total lymphoid irradia-
tion(25) and thymectomy are variations on the same theme. So would be 
pre transplantation conditioning with powerful antilymphocyte sera and 
globulins, an approach that has been made impractical in patients by immune 
reactions to the heterologous protein.(2l) It is clear that a sufficiently long 
conditioning period will be required. 
Today, for the first time in years, there is the real prospect of better 
drugs for core immunosuppression, of which cyclosporin A is the most 
promising, as CaIne has reported. (cf. Chapter 50, this volume). The potential 
value of pretreating with cyclosporin (or other drugs) or alternatively of 
combining drugs with preoperative lymphoid depletion is obvious. With any 
such conditioning effort, the use of the battery of in vitro immunologic tests 
now available should permit the curves of preoperative immunodepression 
to be quantitated for individual patients. 
We have in fact treated four patients with cyclosporin for 24-42 days 
following TDD. The convalescence of these patients has been remarkably 
uncomplicated. Within 1 or 2 days after transplantation, maneuvers were 
begun to discontinue the TDD. No steroids or azathioprine were given. It 
will be interesting to see if cyclosporin itself can be substituted for TDD in 
the pretreatment period. 
6.2. Patient Selection and Histocompatibility 
In the past, renal recipients (particularly those needing cadaveric organs) 
always have been ruled by the donors, with the final decision about candidacy 
hinging mainly on the conventional negative cytotoxic cross match and, in 
most centers, to a lesser extent on HLA matching. With effective pretreatment 
by TDD, it has been possible to give weight to the recipient's wishes. Based 
on the antibody state, a rational decision has been possible about the duration 
of pretreatment and about the prospects for success without any consideration 
of tissue match. Once the TDD is instituted, the patient has been assured of 
transplantation and at a fairly predictable time. The ability to offer trans-
plantation to cadaveric kidney recipients as an elective and planned under-
taking has drastically changed our program. The numbers of consanguineous 
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transplants have dwindled to less than 10% of the total as the prospective 
recipients have perceived the improved cadaveric situation. The number of 
cases that can be handled by our fixed-bed unit has substantially increased 
(60 in the last 7 months), in spite of the time investment for pretreatment 
which is more than canceled by the ability to discharge patients earlier after 
a homograft has been placed. 
6.3. Other Organs 
Improvements in immunosuppression should be applicable for other 
organs including the liver and heart. The direct application of these findings 
in liver recipients may pose special problems. Lymph drainage in patients 
with hepatic disease tends to be voluminous, particularly if ascites is present. 
Recently, we were forced to perform a liver transplant after only 18 days of 
TDD because the amount of lymph obtained per day had reached 25 liters, 
a volume so great that fluid management was becoming difficult. It may be 
that many of the liver recipients can have safer lymphoid depletion by 
lymphapheresis or by other kinds of preoperative conditioning discussed 
earlier. Certainly, pretreatment will be a major factor in patient care as our 
liver transplant program reopens. 
7. Summary 
Pretreatment with TDD markedly influences early graft survival and 
virtually eliminates early rejection, provided that the lymphoid depletion is 
for at least 4 weeks. Such preoperative recipient conditioning has improved 
the quality of patient service. It is probable that the pretreatment principle 
can be applied effectively while using other immunosuppressive measures 
including drugs. 
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